Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients

Basit Öğe Kaydı
dc.contributor.authorUcmaky, Hasan
dc.contributor.authorKoekoglu, Oemer Faruk
dc.contributor.authorHosoglu, Salih
dc.contributor.authorDogan, Ekrem
dc.contributor.authorSayarlioglu, Hayriye
dc.contributor.authorKuzhan, Nuretdin
dc.contributor.authorIsik, Ismet Onder
dc.date.accessioned2024-04-24T16:24:39Z
dc.date.available2024-04-24T16:24:39Z
dc.date.issued2008
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and Aim. Hepatitis C virus (HCV) is prevalent in hemodialysis (HD) patients. The current best therapy for HCV-positive hemodialysis patients is not known. The aim of the present study was to evaluate the long-term efficacy of pegylated interferon (PEG-IFN alpha-2a) in HCV-positive hemodialysis (HD) patients. Materials and Methods. Twenty-five HCV-RNA-positive hemodialysis patients were included into the study. Twelve patients were allocated to the PEG-IFN treatment group (group 1). Six refused the therapy, and seven were not candidates for kidney transplantation and were allocated to the control group (group 2). All patients underwent chronic hemodialysis treatment for end-stage renal disease during the study period. group 1 patients received PEG-IFN alpha-2a at a dose of 135 mu g weekly for 48 weeks. Tire patients were prospectively followed up for a period of 192 weeks. Biochemical and virological responses were evaluated at 144 weeks after the completion of therapy. Results. Two patients in group 1 and five patients in group 2 died during 144 weeks of follow-up. SVR was observed in six patients (50%) in group 1 and one patient (1/13) (7.7%) in group 2. ALT levels were normal in 8/10 (80%) in group 1 and in 5/7 (70%) in group 2. Conclusion. In summary, our data showed that treatment of chronic HCV infection in dialysis patients with PEG-IFN alpha-2a at a dose of up to 135 mu g weekly was well tolerated. Furthermore, SVR was achieved in half of patients at the end of 144 weeks of follow-up. Our results are encouraging for the administration of PEG-IFN alpha-2a in HCV-positive HD patients waiting for kidney transplantation.en_US
dc.identifier.doi10.1080/08860220701813368
dc.identifier.endpage232en_US
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue2en_US
dc.identifier.pmid18300126
dc.identifier.scopus2-s2.0-39749157615
dc.identifier.scopusqualityQ2
dc.identifier.startpage227en_US
dc.identifier.urihttps://doi.org/10.1080/08860220701813368
dc.identifier.urihttps://hdl.handle.net/11468/16804
dc.identifier.volume30en_US
dc.identifier.wosWOS:000253580800017
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis Cen_US
dc.subjectChronic Renal Failureen_US
dc.subjectDialysisen_US
dc.subjectPegylated Interferonen_US
dc.subjectEfficacyen_US
dc.titleLong-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patientsen_US
dc.titleLong-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu